MoonLake Immunotherapeutics
A clinical-stage biopharmaceutical company unlocking the potential of Sonelokimab, a novel investigational Nanobody for the treatment of inflammatory disease.
Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.
The company’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa and psoriatic arthritis – conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland.
Latest MoonLake Immunotherapeutics News & Features
11 March 2024
22 January 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze